2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

References

• Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1069
   PubMed Web of Science ®Google Scholar
• Carson D. A., Kaye J., Seegmiller J. E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency, Possible role of nucleo-side kinase(s). Proc. Natl. Acad. Sci. USA 1977; 74: 5677–5681
   PubMed Web of Science ®Google Scholar
• Agarwal R. P., Crabtree G. W., Parks R. E., Jr., Nelson J. A., Keightley R., Parkman R., Rosen F. S., Stern R. C., Polmar S. H. Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency. J. Clin. Invest 1976; 57: 1025–1035
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Kaye J., Ullman B., Martin D. W., Jr., Robins R. K., Montgomery J. A. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. USA 1980; 77: 6865–6869
   PubMed Web of Science ®Google Scholar
• Seto S., Carrera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2-chlorodeox-yadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. USA 1984; 81: 2232–2236
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. 2-Chlorodeoxyadenosine (CdA) in lymphoproliferative diseases, Clinical and pharmaco-kinetic studies. Blood (Suppl I) 1990; 76: 354a
   PubMedGoogle Scholar
• Carrera C. J., Terai C., Lotz M., Curd J. G., Piro L. D., Beutler E., Carson D. A. Potent toxicity of 2-chlorodeoxyadenosine towards human monocytes in vitro and in vivo, A novel approach to immunosuppressive therapy. J. Clin. Invest 1990; 86: 1480–1488
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Lamon J., Beutler E. A potent new anti-lymphocyte agent, 2-chlorodeoxyadenosine. Blood 1982; 60, (Supplement 1)
   PubMedGoogle Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine, An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1989; 74: 239a
   Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2-Chlorodeoxyadenosine, An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1973
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. Phase II trial update of 2-chlorodeoxyadenosine treatment of advanced chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol 1990; 9: 212a
   Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia. Recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Hematol 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Kay A. C., Carrera C. J., Carson D. A., Beutler E., Piro L. D. Phase II trial of 2-chlorodeoxyadenosine in low-grade lymphoma. Blood 1989; 74: 121a
   Google Scholar
• Piro L. D., Miller W. E., Carrera C. J., Carson D. A., Beutler E. Hairy-cell leukemia. N. Engl. J. Med 1987; 317: 901
   PubMedGoogle Scholar
• Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Piro L. D., Saven A., Cox K., Beutler E., Carson D. A., Kipps T. J. Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 1990; 76: 260A, (Suppl)
   Google Scholar
• Carson D. A., Kaye J., Wasson D. B. The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J. Immunol 1981; 126: 348–352
   PubMed Web of Science ®Google Scholar
• Agarwal R. P., Spector T., Parks R. E., Jr. Tight-binding inhibitors—IV. Inhibition of adenosine deaminases by various inhibitors. Biochem. Pharmacol 1976; 26: 359–367
   Web of Science ®Google Scholar
• Lembersky B. C., Ratain M. J., Westbrook C., Colomb H. M. Rapid response to 2′-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma. Am. J. Hematol 1988; 27: 60–62
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Eisenhauer E., Corbett W. E., Scott J. G., Zaentz S. D. Efficacy of 2′-deoxycoformycin in hairy-cell leukemia, a study of the National Cancer Institute of Canada Clinical Trials Group. JNCI 1988; 80: 765–769
   PubMed Web of Science ®Google Scholar
• Spiers A. S., Parekh S. J. The treatment of hairy cell leukemia with 2′-deoxycoformycin, results in India and in the United States. Leukemia 1987; 1: 347–350
   PubMed Web of Science ®Google Scholar
• Blick M., Lepe-Zuniga J. L., Doig R., Quesada J. R. Durable complete remissions after 2′-deoxycoformycin treatment in patients with hairy cell leukemia resistant to interferon alpha. Am. J. Hematol 1990; 33: 205–209
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Yu A. L., Qiao C.-N. Repeated pentostatin (2′-deoxycoformycin)-induced remissions in a patient with advanced chronic lymphocytic leukemia. West. J. Med 1988; 148: 334–337
   PubMedGoogle Scholar
• Kraut E. H., Neff J. C., Bouroncle B. A., Gochnour D., Grever M. R. Immunosuppressive effects of pentostatin. J. Clin. Oncol 1990; 8: 848–855
   PubMed Web of Science ®Google Scholar
• Lindley C. M., Bernard S. A., Robertson J. D. Vomiting associated with pentostatin and pentostatin plus alpha-interferon, unique pattern and potential mechanisms. J. Pain Symptom. Manage 1990; 5: 262–264
   PubMedGoogle Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine, A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Schachner J., Keating M. J. Fludarabine therapy in hairy cell leukemia. Cancer 1991; 67: 1291–1293
   PubMed Web of Science ®Google Scholar